Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Contineum Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Contineum Therapeutics's regulatory disclosures and financial reporting.
Contineum Therapeutics, Inc. CEO and President Carmine N. Stengone exercised stock options for 2,500 shares of Class A common stock at an exercise price of $1.01 per share and sold 2,500 shares at a weighted average price of $16.0116 per share, with trades between $16.00 and $16.06. The options were granted under the company’s 2012 Equity Incentive Plan and are fully vested, leaving 276,930 options outstanding after the exercise. All reported transactions on August 3, 2026 were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025.
CTNM reports that an affiliate, Morgan Stanley Smith Barney LLC Executive Financial Services, intends to sell 2,500 shares of common stock on NASDAQ on August 3, 2026, in connection with an exercise of stock options for cash. The filing also lists prior sales under a Rule 10b5-1 trading plan for Carmine Stengone, including 2,500 common shares sold on July 8, 2026 for $40,000.00 and 10,000 common shares sold on June 30, 2026 for $160,080.00.
CTNM insider Daniel Lorrain has filed to sell common stock under Form 144. The planned sale involves 9,520 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on August 3, 2026 on NASDAQ.
The shares relate to equity awards including 4,170 restricted stock units granted on May 9, 2017 and an exercise of stock options for 5,350 shares dated August 3, 2026, with cash as the payment method for the option exercise. The filing also lists recent Rule 10b5-1 plan sales of CTNM common stock by Lorrain over the prior three months in multiple tranches.
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies for inflammatory and fibrotic diseases. Lead asset PIPE-791, an LPAR1 inhibitor, is in PROPEL-IPF, a global Phase 2 trial in idiopathic pulmonary fibrosis, and has shown encouraging Phase 1b data in chronic pain. Partnered drug PIPE-307, an M1 receptor inhibitor licensed to J&J, is in a Phase 2 depression study (Moonlight-1) with 107 participants enrolled.
For the quarter ended June 30, 2026, the company reported no revenue, operating expenses of $17.4 million and a net loss of $15.2 million, or $0.40 per share$24.3 million and general and administrative expenses were $10.0 million, leading to a six‑month net loss of $29.6 million.
Liquidity remains strong, with $236.6 million in cash, cash equivalents and marketable securities as of June 30, 2026. Management states these resources are expected to fund operations for at least 12 months. An amended at‑the‑market program permits up to $100.0 million of additional Class A common stock sales, none of which were used in the first half of 2026.
Contineum Therapeutics reported second-quarter 2026 results and progress across its pipeline of oral small-molecule drugs for inflammatory and fibrotic diseases. The company is dosing patients in PROPEL-IPF, a 26-week global Phase 2 trial of PIPE-791 in approximately 324 idiopathic pulmonary fibrosis patients, with over 55 sites active in eight countries. Johnson & Johnson completed enrollment of 107 adults in the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder. PIPE-791 also produced positive topline safety and exploratory pain data in an exploratory Phase 1b chronic pain study.
Contineum streamlined discovery efforts and implemented a limited workforce reduction, including the departure of Chief Scientific Officer Daniel Lorrain, to focus resources on its highest-potential programs. Cash, cash equivalents and marketable securities were $236.6 million as of June 30, 2026, and the company believes this supports operations through mid-2029. In the quarter, research and development expenses were $12.7 million (down 10% year over year), general and administrative expenses were $4.7 million (up 23%), and net loss was $15.2 million compared with $16.0 million a year earlier.
BlackRock, Inc. reports beneficial ownership of Class A stock of THERAPEUTICS INC. BlackRock and certain of its subsidiaries and affiliates, described as the reporting business units, collectively beneficially own 2,049,493 shares of Class A stock, representing 6.3% of the outstanding class.
BlackRock has sole voting power over 2,030,054 shares and sole dispositive power over 2,049,493 shares, with no shared voting or dispositive power. The position is held on behalf of various underlying clients of BlackRock’s investment management businesses. Various persons may receive dividends or sale proceeds from these shares, but no single such person is identified as holding more than five percent of THERAPEUTICS INC’s outstanding common shares.
Contineum Therapeutics, Inc. has an amended Schedule 13G reporting that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander collectively report beneficial ownership of 931,709 shares of Class A common stock. This represents 2.8% of the class.
The shares are reported with shared voting and shared dispositive power and no sole voting or dispositive power. The securities are held by entities over which Millennium Management LLC and related investment managers exercise voting control and investment discretion, with Millennium Group Management LLC as managing member and Mr. Englander as sole voting trustee of its managing member. The filers state that this structure should not by itself be construed as an admission of beneficial ownership. They also indicate that they hold 5 percent or less of the class.
Contineum Therapeutics, Inc. furnished an updated corporate overview describing its pipeline of small-molecule therapies targeting diseases with significant unmet need, led by PIPE-791, a brain-penetrant LPAR1 antagonist in development for idiopathic pulmonary fibrosis (IPF) and chronic pain.
The company highlights clinical validation of the LPAR1 target in IPF/PPF and describes PIPE-791 as a once-daily oral candidate with high and sustained receptor occupancy and favorable Phase 1 safety. A global Phase 2 IPF trial is underway with approximately 324 subjects and an estimated completion in June 2028. Early Phase 1B data in chronic pain show a favorable safety profile and numerically better pain outcomes versus placebo.
The overview also describes PIPE-307 (JNJ-5120), a selective M1R antagonist for major depressive disorder partnered with Janssen under a deal including $50 million upfront cash, a $25 million equity investment, and over $1 billion in potential milestones, with royalties from low-double digits to high-teens. Management states that existing cash and cash equivalents are projected to provide a cash runway through mid-2029.
Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported paired option exercises and stock sales in Class A Common Stock. He exercised options covering 1,040 shares at $1.01 per share and sold 1,040 shares at $16.00 per share in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025. Following these transactions, he holds 135,202 shares directly and 10,110 shares indirectly through his spouse.
Contineum Therapeutics CEO Carmine N. Stengone reported an option exercise and share sale in Class A Common Stock. He exercised stock options for 2,500 shares at $1.01 per share and sold 2,500 shares at $16.00 per share on July 8, 2026. These trades were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025. After the transactions, he holds 17,217 shares directly and 279,430 stock options expiring on February 24, 2030.